The mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are used to prevent organ transplant rejection and minimize side effects such as infection.1, 2The mTOR inhibitors have advantages of low nephrotoxicity compared with other immunosuppressants, but various adverse effects have been reported including thrombocytopenia, dyslipidemia, delayed wound healing, and in rare cases, lymphedema. This evidence concerns the gene MTOR and metabolic syndrome.